Susannah Walpole - Spero Therapeutics Head Operations
| SPRO Stock | USD 1.16 0.03 2.52% |
Insider
Susannah Walpole is Head Operations of Spero Therapeutics
| Address | 675 Massachusetts Avenue, Cambridge, MA, United States, 02139 |
| Phone | 857 242 1600 |
| Web | https://sperotherapeutics.com |
Spero Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.1048 % which means that it generated a profit of $0.1048 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2581 %, meaning that it created $0.2581 on every $100 dollars invested by stockholders. Spero Therapeutics' management efficiency ratios could be used to measure how well Spero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to 0.13. Also, Return On Capital Employed is likely to grow to 0.16. At this time, Spero Therapeutics' Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nicole White | Assembly Biosciences | N/A | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| Timothy Moore | Instil Bio | 63 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
| Hoyoung MD | CytomX Therapeutics | 55 | |
| W Vernon | Nuvation Bio | 65 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| Julia Wilson | Achilles Therapeutics PLC | N/A | |
| Dr IV | Assembly Biosciences | 52 | |
| Michelle Doig | Nuvation Bio | 46 | |
| AO FRACP | Assembly Biosciences | 65 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Sandeep MD | Instil Bio | 55 | |
| David MD | Nuvation Bio | 54 | |
| Solomon Langermann | NextCure | 64 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Sergey Yurasov | Nuvation Bio | 51 | |
Management Performance
Spero Therapeutics Leadership Team
Elected by the shareholders, the Spero Therapeutics' board of directors comprises two types of representatives: Spero Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spero. The board's role is to monitor Spero Therapeutics' management team and ensure that shareholders' interests are well served. Spero Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spero Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Satyavrat CFA, CFO Treasurer | ||
| James Brady, Chief Officer | ||
| Ted Jenkins, VP Relations | ||
| Ian Critchley, Head Microbiology | ||
| Susannah Walpole, Head Operations | ||
| Esther Rajavelu, CFO Officer | ||
| Timothy Keutzer, Senior Vice President - Development | ||
| Angela MD, VP Devel | ||
| MBA MD, President, CoFounder | ||
| Tamara LLM, Chief Secretary |
Spero Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spero Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | (1.87) % | ||||
| Current Valuation | (8.43 M) | ||||
| Shares Outstanding | 54.52 M | ||||
| Shares Owned By Insiders | 20.13 % | ||||
| Shares Owned By Institutions | 23.04 % | ||||
| Number Of Shares Shorted | 625.19 K | ||||
| Price To Earning | 81.20 X |
Pair Trading with Spero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Spero Stock
Moving against Spero Stock
The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.
The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.08 | Revenue Per Share 2.223 | Quarterly Revenue Growth 2.754 | Return On Assets 0.1048 |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.